Pfizer expects 8 blockbuster cancer drugs to come from each of 4 focus areas: exec
Fierce Pharma
JUNE 13, 2024
Pfizer's oncology division plans to have eight blockbusters by 2030, with contributions from each of its four focused therapeutic areas.
Thu.Jun 13, 2024
290 
Modifier gene therapy – clinical development and manufacturing considerations
European Pharmaceutical Review
JUNE 13, 2024
Tell us about Ocugen’s lead programme, OCU400. What’s the latest and what’s next? OCU400 is a modifier gene therapy aimed at treating retinitis pigmentosa and Leber congenital amaurosis (LCA). In April 2024, Ocugen received US Food and Drug Administration (FDA) clearance to initiate the Phase III liMeliGhT clinical trial for OCU400 for retinitis pigmentosa.
Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
With phase 3 miss, Pfizer's DMD candidate is no threat to Sarepta's Elevidys ahead of key label expansion: analysts
Fierce Pharma
JUNE 13, 2024
With a phase 3 miss following a fatality in a related study and marking what analysts are calling the “final nail” in Pfizer’s Duchenne muscular dystrophy (DMD) gene therapy coffin, Sarepta Therape | With a phase 3 miss and severe safety signals, Pfizer's Duchenne muscular dystrophy gene therapy candidate is no competition to Sarepta's established Elevidys, according to analysts.
Pfizer & Sarepta Gene Therapies Both Failed Phase 3, But Analysts Expect Sarepta Will Win Approval
MedCity News
JUNE 13, 2024
A Pfizer gene therapy for Duchenne muscular dystrophy failed its Phase 3 clinical trial. But analysts draw distinctions between that therapy and Sarepta Therapeutics’ Elevidys, which awaits an FDA decision that could grant it full regulatory approval. The post Pfizer & Sarepta Gene Therapies Both Failed Phase 3, But Analysts Expect Sarepta Will Win Approval appeared first on MedCity News.
AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Talc plaintiffs file for restraining order to block Johnson & Johnson's 3rd bankruptcy attempt
Fierce Pharma
JUNE 13, 2024
As Johnson & Johnson has tried to resolve talcum powder lawsuits that have been consolidated in a multidistrict litigation in New Jersey, the company has had to deal with two groups of plaintif | J&J has had to deal with two groups of plaintiffs in its talc lawsuits—one that wants to accept a settlement and the other that doesn’t. Now, the latter group has asked a New Jersey federal court to issue a restraining order to block a J&J subsidiary from filing for bankruptcy.
The Potential for AI in Drug Design
MedCity News
JUNE 13, 2024
Despite misconceptions about its use, artificial intelligence (AI), through modalities such as machine learning models, is poised to enable companies to expedite the drug design process. The post The Potential for AI in Drug Design appeared first on MedCity News.
Sign up to get articles personalized to your interests!
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
More Trending
Mahana’s DTx for IBS gets permanent reimbursement in Germany
pharmaphorum
JUNE 13, 2024
Mahana Therapeutics has granted permanent reimbursement in Germany for its Cara Care digital therapeutic for irritable bowel syndrome
Investment firm Great Point Partners scoops up German CDMO Lyocontract
Fierce Pharma
JUNE 13, 2024
On a mission to debut life science companies on the global stage, healthcare investment firm Great Point Partners is making a play for private German contract development and manufacturing organiza | On a mission to debut life science companies on the global stage, healthcare investment firm Great Point Partners is making a play for private German contract development and manufacturing organization Lyocontract.
Future of Pfizer’s Duchenne gene therapy in doubt
pharmaphorum
JUNE 13, 2024
Pfizer is “evaluating next steps” for its Duchenne muscular dystrophy (DMD) gene candidate after it failed a phase 3 trial
AmeriHealth Caritas Exec: Worst Thing Insurers Can Do Is Be Paralyzed by AI Challenges
MedCity News
JUNE 13, 2024
Payers face numerous challenges when it comes to AI, but that doesn’t mean they shouldn’t use the technology, according to Neil Gomes, senior vice president and chief digital officer of AmeriHealth Caritas. The post AmeriHealth Caritas Exec: Worst Thing Insurers Can Do Is Be Paralyzed by AI Challenges appeared first on MedCity News.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
FDA approves AstraZeneca’s Farxiga for paediatric T2D patients
Pharmaceutical Technology
JUNE 13, 2024
The US FDA has granted approval for AstraZeneca's Farxiga for paediatric patients aged 10 years and above with type-2 diabetes.
WuXi buoyed as BIOSECURE Act is left out of US spending bill
pharmaphorum
JUNE 13, 2024
Shares in WuXi Biologics and WuXi AppTec rose after the BIOSECURE Act was omitted from legislation due to be followed up in congress.
LifeArc funds new projects to address and prevent global threat of dengue fever
PharmaTimes
JUNE 13, 2024
The mosquito-borne viral disease is responsible for an estimated 390 million cases globally
How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Flagship, ProFound set off on obesity drug hunt for Pfizer
pharmaphorum
JUNE 13, 2024
Pfizer has had some setbacks in its efforts to develop drugs for the lucrative obesity market, but could see its pipeline swell thanks to its $7 billion partnership with venture capital firm Flagship Pioneering. Flagship has just announced that it will work with biotech startup ProFound Therapeutics to find first-in-class protein therapeutics with potential in obesity, confirming this is the first programme in the alliance with Pfizer signed last July.
Alzheon secures $100m to advance Alzheimer’s disease treatment
Pharmaceutical Technology
JUNE 13, 2024
Alzheon has secured $100m in a Series E funding round to develop and commercialise ALZ-801 for Alzheimer's disease (AD).
Being an Ally Isn’t Just for Pride Month
ALULA
JUNE 13, 2024
Every June, companies plaster rainbow flags across their logos in a show of LGBTQIA+ "allyship" for Pride Month. But true allyship isn't just a celebration - it's an ongoing commitment to supporting LGBTQIA+ individuals every day.
Haemophilia drug could reduce treated bleeding episodes
European Pharmaceutical Review
JUNE 13, 2024
A next-generation FVIIIa mimetic bispecific antibody has demonstrated statistically significant and superior reduction of treated bleeding episodes in haemophilia A, new headline data from a pivotal Phase IIIa trial show. Mim8 was evaluated in participants aged 12 years or older as both a once-weekly and once-monthly treatment versus no prophylaxis treatment and prior coagulation factor prophylaxis treatment.
Global medicines and the future outlook
pharmaphorum
JUNE 13, 2024
In a conversation held earlier in the year as the four-year anniversary of the pandemic approached, the pharmaphorum podcast had as guest Murray Aitken, executive director of the IQVIA Institute for Human Data Science, to discuss the state of global medicines and the future outlook when it comes to research and development, and usage and spending appetites.
Sysmex receives Longitude Prize on AMR for antimicrobial testing system
PharmaTimes
JUNE 13, 2024
AMR is designated as one of the top ten global public health threats facing humanity by WHO
Streamlining Aseptic Processes through Automation
PharmaTech
JUNE 13, 2024
Leveraging automation advancements can help improve efficiency in aseptic processing and speed up commercialization of critical drug products.
How Covered Entities and Pharma Companies Can Better Collaborate on Drug Discount Programs
MedCity News
JUNE 13, 2024
Three things drug manufacturers and CEs can do to build trust and enable effective collaboration The post How Covered Entities and Pharma Companies Can Better Collaborate on Drug Discount Programs appeared first on MedCity News.
Increase Revenue With Better, Faster Sales Onboarding
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
FDA Approves Tralokinumab-ldrm Autoinjector for Adults With Atopic Dermatitis
Pharmacy Times
JUNE 13, 2024
The autoinjector will provide another option for adults in addition to the prefilled syringe that is currently available.
NHS and ABPI announce new guidelines ahead of UK elections
Pharmaceutical Technology
JUNE 13, 2024
The new guidelines outline ways to develop NHS-industry partnerships and follow the ABPI’s manifesto.
Implications for Pharmacies Navigating Shared Clinical Decision-Making in Vaccination
Pharmacy Times
JUNE 13, 2024
The SCDM model demands more than the traditional roles assigned to pharmacists, requiring an enhanced level of patient engagement, medical knowledge, and legal authority to implement effectively
How to increase specialist engagement in accountable care organizations
Clarify Health
JUNE 13, 2024
Medicare is a pioneer in advancing value-based care, specifically its use of Accountable Care Organization (ACO) frameworks. Alternative Payment Models (APMs) are payment approaches that incentivize quality and value in healthcare delivery by rewarding providers for cost-efficient care and improved patient outcomes. Progressive APMs incentivize ACOs to deliver the best possible care, especially for patients with complex conditions that require multiple costly treatments—which describes the major
Novel Treatments Could Turn the Tide for Alzheimer Disease
Pharmacy Times
JUNE 13, 2024
Anti-amyloid antibody administration decreased plaque volume in clinical trials of patients with early AD, indicating that passive immunotherapies could be a promising treatment for the disease.
Revamp your MLR review with these 7 data-driven strategies
Vodori
JUNE 13, 2024
In today's fast-paced marketing landscape, ensuring the efficiency and effectiveness of promotional materials is more crucial than ever. The Medical, Legal, and Regulatory (MLR) review process plays a vital role in this, acting as the gatekeeper for compliance and quality.
Understanding Excipient Characteristics to Ensure Robust Continuous Manufacturing
PharmaTech
JUNE 13, 2024
Key information is needed for excipients and their potential impact on continuous manufacturing processes.
AbbVie Presents New Data from Antibody-Drug Conjugates Across Multiple Indications at ASCO 2024
PharmExec
JUNE 13, 2024
In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses data presented at ASCO from ABBV-400 and ABBV-706 in multiple studies.
Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Let's personalize your content